Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted - GBI Research Reports

Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted

Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted - GBI Research Reports
Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted
Published Nov 22, 2011
216 pages — Published Nov 22, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted which provides an insight into different endpoints that are used for the central nervous system (CNS) in clinical trials. The report examines different aspects under clinical trial endpoints in central nervous system disorders such as analysis on major marketed central nervous system drugs with an emphasis on safety and efficacy details. Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, most promising central nervous system drugs with details on safety, efficacy and clinical trials, and terminated trial analysis. The company profiling highlights the central nervous system drugs of different companies.

The global CNS disease market is valued as $53.1 billion in 2010 that grew from $36.8 billion in 2002 with a CAGR of 4.7%. An increased geriatric population in many countries combined with increased life expectancy is expected to increase disease population of CNS disease. The product pipeline of CNS disease is promising with many novel molecules with disease modifying characteristics at various stages of development and is expected to fulfill the unmet needs in the CNS disease market. The product pipeline for multiple sclerosis has many orally administered novel molecules whereas for alzheimers disease, the product pipeline have novel molecules such as Bapineuzumab, Solanezumab, BMS-708163 that target the underlying causes of the disease and thus may offer significant benefits to the patients. The market for Schizophrenia and bipolar disorder is estimated to be driven by the anticipated launch of AZ-004 and other molecules such as Cariprazine, Zicronapine, RG1678 and Aripiprazole Depot injection. The continued uptake of non stimulants and expected launch of Kapvay and other pipeline molecules will have significant impact on market for ADHD. Although in upcoming years the market will witness patent expiries of major drugs, however this will be offset by the rapid uptake of new molecules, which will stabilize the market decline. The market is expected to grow with a CAGR of 1.4% from 2010 to 2017 to reach $58.6 billion in 2017.

This report details Endpoints Clinical Trials in Central nervous system Disorders, highlighting the five major central nervous system disorders which are Alzheimers disease, Depression, Epilepsy, Parkinsons disease and Schizophrenia. The classification of five major central nervous system diseases is done on the basis of, the number of pipeline molecules present in Phase III stage of development.

The term endpoint refers to an outcome or measure of a clinical trial. Endpoints can include all kinds of aspects, those related to the effectiveness of treatment and others. However, the endpoint selection must take into account the need to obtain the highest information of therapeutic interest with the least risk and discomfort for the individual. Also, the endpoints must be to the objective of the study and represent the most effective way to assess pharmacological response.

Scope

- Data and analysis on the marketed products and analysis of their efficacy and safety details
- Analysis of the five major Central nervous system diseases which include Alzheimers disease, depression, epilepsy, Parkinsons disease and schizophrenia
- Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Also analysis of terminated trials is included in this chapter. Only industry sponsored studies are included in the report.
- Analysis on most promising molecules of five major central nervous system diseases with emphasis on their efficacy and safety details.
- Company Profiling talks

  
Source:
Document ID
GBIHC140MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents39
  List of Tables52
  List of Figures75
Clinical Trial Design in Central Nervous System - Overview122
  Introduction121
  Types of Clinical Trial Outcomes121
    Primary Outcomes121
    Secondary Outcomes121
  GBI Research Report Guidance131
Endpoints - Clinical Trials in CNS Disorders - Top Five CNS Disorders and their Product Profiling144
  Endpoints-Major Marketed Drugs of Top Five Central Nervous System Disorders and their Regulatory Approval141
    Alzheimer s disease151
    Depression151
    Epilepsy161
    Parkinson s disease161
    Schizophrenia171
Endpoints - Clinical Trials in CNS Disorders Marketed and Pipeline Product Assessments18183
  Alzheimer s disease181
    Primary Endpoints used in Alzheimer s disease Clinical Trials191
    Secondary Endpoints used in Alzheimer s disease Clinical Trials191
    Major Marketed Drugs-Safety and Efficacy Analysis191
      Aricept (donepezil hydrochloride)192
      Exelon (rivastigmine titrate)211
      Namenda (memantine hydrochloride)221
      Cognex231
      Razadyne (galantamine hydrobromide extended release capsules)241
    Phase III Clinical Trial Analysis251
      Primary Endpoints of Phase III Completed Trials253
      Secondary Endpoints of Phase III Completed Trials287
      Primary Endpoints of Phase III Ongoing Trials352
      Secondary Endpoints of Phase III Ongoing Trials374
    Most Promising Drugs Profiles411
      Bapineuzumab411
      Gammagard421
      Dimebon431
      Rember (Trx0014) (methylthionium chloride)432
    Phase II Clinical Trial Analysis451
      Primary Endpoints of Phase II Completed Trials453
      Secondary Endpoints of Phase II Completed Trials487
      Primary Endpoints of Phase II Ongoing Trials552
      Secondary Endpoints of Phase II Ongoing Trials574
    Terminated Trials Analysis611
  Depression621
    Primary Endpoints used in Clinical Trials for Depression631
    Secondary Endpoints used in Clinical Trials for Depression631
    Major Marketed Drugs-Safety and Efficacy Analysis641
      Lexapro/Cipralex (Escitalopram oxalate)641
      Cymbalta (Duloxetine Hydrochloride)651
      Abilify (Aripiprazole)661
      Pristiq (Desvenlafaxine succinate)671
      Symbyax (Olanzapine and fluoxetine Hcl)681
      Viibryd (Vilazodone Hydrochloride)691
    Phase III Clinical Trial Analysis701
      Primary Endpoints of Phase III Completed Trials703
      Secondary Endpoints of Phase III Completed Trials736
      Primary Endpoints of Phase III Ongoing Trials791
      Secondary Endpoints of Phase III Ongoing Trials791
    Most Promising Drugs Profiles791
      TC 5214791
      LU AA21004801
    Phase II Clinical Trial Analysis811
      Primary Endpoints of Phase II Completed Trials813
      Secondary Endpoints of Phase II Completed Trials843
      Primary Endpoints of Phase II Ongoing Trials871
      Secondary Endpoints of Phase II Ongoing Trials871
    Terminated Trials Analysis871
  Epilepsy881
    Primary Endpoints used in Clinical Trials for Epilepsy891
    Secondary Endpoints used in Clinical Trials for Epilepsy901
    Major Marketed Drugs-Safety and Efficacy Analysis901
      Drug Name Lyrica (Pregabalin)902
      Gabitril (Tiagabine Hcl)921
      Banzel (Rufinamide)931
      Vimpat (Lacosamide)941
      Sabril (Vigabatrin)951
    Phase III Clinical Trial Analysis961
      Primary Endpoints of Phase III Completed Trials962
      Secondary Endpoints of Phase III Completed Trials987
      Primary Endpoints of Phase III Ongoing Trials1051
      Secondary Endpoints of Phase III Ongoing Trials1062
    Most Promising Drugs Profiles1081
      Stedesa (Eslicarbazepine Acetate)1081
      Comfyde (Carisbamate)1091
      Retigabine1101
      Brivaracetam1111
      Ganaxolone1121
      E2007 (Perampanel)1131
    Phase II Clinical Trial Analysis1141
      Primary Endpoints of Phase II Completed Trials1142
      Secondary Endpoints of Phase II Completed Trials1165
      Primary Endpoints of Phase II Ongoing Trials1211
      Secondary Endpoints of Phase II Ongoing Trials1211
    Terminated Trials Analysis1221
  Parkinson s disease1231
    Primary Endpoints used in Clinical Trials for Parkinson s disease1231
    Secondary Endpoints used in Clinical Trials Parkinson s disease1241
    Major Marketed Drugs-Safety and Efficacy Analysis1241
      Stalevo (levodopa, carbidopa, entacapone)1241
      Requip XL (ropinirole XL)1251
      Azilect (rasagiline mesylate)1261
      Mirapex/Sifrol/Mirapexin (pramipexole dihydrochloride)1271
      Comtan (entacapone)1281
      Tasmar (tolcapone)1291
    Phase III Clinical Trial Analysis1301
      Primary Endpoints of Phase III Completed Trials1303
      Secondary Endpoints of Phase III Completed Trials1337
      Primary Endpoints of Phase III Ongoing Trials1401
      Secondary Endpoints of Phase III Ongoing Trials1413
    Most Promising Drugs Profiles1441
      Safinamide1441
      Pimavanserin (ACP-103)1451
      PD-021461
      SLV 308 (pardoprunox)1471
      Lisuride (patch and subcutaneous (sc) infusion)1471
      IPX0661481
    Phase II Clinical Trial Analysis1491
      Primary Endpoints of Phase II Completed Trials1493
      Secondary Endpoints of Phase II Completed Trials1526
      Primary Endpoints of Phase II Ongoing Trials1582
      Secondary Endpoints of Phase II Ongoing Trials1602
    Terminated Trials Analysis1621
  Schizophrenia1631
    Primary Endpoints used in Clinical Trials for Schizophrenia1641
    Secondary Endpoints used in Clinical Trials for Schizophrenia1641
    Major Marketed Drugs-Safety and Efficacy Analysis1651
      Zyprexa (olanzapine)1651
      Abilify (aripiprazole)1651
      Seroquel/Seroquel XR (quetiapine)1661
      Geodon (ziprasidone)1671
      Invega (paliperidone)1681
      Fanapt (iloperidone)1681
      Saphris (asenapine)1691
      Serdolect (sertindole)1701
    Phase III Clinical Trial Analysis1711
      Primary Endpoints of Phase III Completed Trials1714
      Secondary Endpoints of Phase III Completed Trials17510
      Primary Endpoints of Phase III Ongoing Trials1851
      Secondary Endpoints of Phase III Ongoing Trials1862
    Most Promising Drugs Profiles1881
      Lurasidone1881
      Cariprazine (RGH-188)1881
      LY21400231891
      Staccato Loxapine, AZ-0041901
    Phase II Clinical Trial Analysis1911
      Primary Endpoints of Phase II Completed Trials1913
      Secondary Endpoints of Phase II Completed Trials1944
      Primary Endpoints of Phase II Ongoing Trials1981
      Secondary Endpoints of Phase II Ongoing Trials1991
    Terminated Trials Analysis2001
Endpoints - Clinical Trials in CNS Disorders - Company Profiles20112
  Pfizer Inc.2011
    Company Profile2011
    Major Central Nervous System Disorders Products2011
  GlaxoSmithKline Plc2021
    Company Profile2021
    Major Central Nervous System Disorders Products2021
  AstraZeneca Plc2031
    Company Profile2031
    Major Central Nervous System Disorders Products2031
  Sanofi2041
    Company Profile2041
    Major Central Nervous System Disorders Products2041
  Johnson &Johnson2051
    Company Profile2051
    Major Central Nervous System Disorders Products2052
  Eli Lilly and Company2071
    Company Profile2071
    Major Central Nervous System Disorders Products2071
  Novartis AG2081
    Company Profile2081
    Major Central Nervous System Disorders Products2082
  Abbott Laboratories2101
    Company Profile2101
    Major Central Nervous System Disorders Products2101
  Forest Laboratories, Inc2111
    Company Profile2111
    Major Central Nervous System Disorders Products2111
  Eisai Co., Ltd2121
    Company Profile2121
    Major Central Nervous System Disorders Products2121
Endpoints - Clinical Trials in CNS Disorders - Appendix2134
  Market Definitions2131
  Abbreviations2131
  Research Methodology2142
    Clinical Trial Design Overview2151
    Marketed and Pipeline Products Assessment2151
    Company Profiles2151
  Contact Us2161
  Disclaimer2161
  Sources2161

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted" Nov 22, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Endpoints-Clinical-Trials-in-CNS-Disorders-Multiple-Endpoints-and-Ratings-Scales-are-Becoming-More-Widely-Adopted-2115-303>
  
APA:
GBI Research Reports. (2011). Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted Nov 22, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Endpoints-Clinical-Trials-in-CNS-Disorders-Multiple-Endpoints-and-Ratings-Scales-are-Becoming-More-Widely-Adopted-2115-303>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.